Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Published:2022-07 Issue:7 Volume:23 Page:888-898
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Motzer Robert J,Powles Thomas,Burotto Mauricio,Escudier Bernard,Bourlon Maria T,Shah Amishi Y,Suárez Cristina,Hamzaj Alketa,Porta Camillo,Hocking Christopher M,Kessler Elizabeth R,Gurney Howard,Tomita Yoshihiko,Bedke Jens,Zhang Joshua,Simsek Burcin,Scheffold Christian,Apolo Andrea B,Choueiri Toni K

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

2. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma;Powles;Ann Oncol,2021

3. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial;Cella;Lancet Oncol,2022

5. A multiple testing procedure for clinical trials;O'Brien;Biometrics,1979

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety;Urologic Oncology: Seminars and Original Investigations;2024-11

2. Identification of tumor-antigen signatures and immune subtypes for messenger RNA vaccine selection in advanced clear cell renal cell carcinoma;Surgery;2024-09

3. Oncolytic viruses facilitate tumor immunotherapy;SCIENTIA SINICA Vitae;2024-09-01

4. A Phase I open-label study of cediranib plus etoposide and cisplatin as first-line therapy for patients with extensive-stage small-cell lung cancer or metastatic neuroendocrine non-small-cell lung cancer;Clinical Lung Cancer;2024-09

5. The role of NCAPH in cancer treatment;Cellular Signalling;2024-09